2015
DOI: 10.1038/aps.2015.32
|View full text |Cite
|
Sign up to set email alerts
|

The role of the dynorphin/κ opioid receptor system in anxiety

Abstract: Anxiety disorders are the most common and prevalent forms of psychiatric disease, although the biological basis of anxiety is not well understood. The dynorphin/κ opioid receptor system is widely distributed in the central nervous system and has been shown to play a critical role in modulating mood and emotional behaviors. In the present review, we summarize current literature relating to the role played by the dynorphin/κ opioid receptor system in anxiety and κ opioid receptor antagonists as potential therape… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

6
47
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 61 publications
(53 citation statements)
references
References 94 publications
6
47
0
Order By: Relevance
“…The anti-anxiety responses of norBNI in the NIH and EPM tests are in line with several publications on anxiolytic-like effects of the long-acting KOPR antagonists norBNI, JDTic, GNTI and DIPPA in rat or mouse tests of anxiety, including the EPM, NIH, defensive burying, open field and fear-potentiated startle tests (see [4;5] for reviews).…”
Section: Discussionsupporting
confidence: 85%
See 2 more Smart Citations
“…The anti-anxiety responses of norBNI in the NIH and EPM tests are in line with several publications on anxiolytic-like effects of the long-acting KOPR antagonists norBNI, JDTic, GNTI and DIPPA in rat or mouse tests of anxiety, including the EPM, NIH, defensive burying, open field and fear-potentiated startle tests (see [4;5] for reviews).…”
Section: Discussionsupporting
confidence: 85%
“…or s.c.) were carried out in a volume of 0.1 ml per 10 g of body weight. Doses used for zyklophin and norBNI were chosen following previous publications [5;8], and that for LY2444296 selected based on its dose responses in forced swim tests (our unpublished data).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…κOR activation leads to antinociception without the side effects associated with μOR activation such as physical dependence, respiratory depression, or inhibition of gastrointestinal transit (4,5). In addition, κOR agonists have antipruritic effects and can block the effects of psychostimulants (6)(7)(8). Thus, κOR agonists could be potential therapeutics to treat addiction, visceral pain, pruritus, or pain killers with low abuse potential (9)(10)(11)(12).…”
mentioning
confidence: 99%
“…Thus, κOR agonists could be potential therapeutics to treat addiction, visceral pain, pruritus, or pain killers with low abuse potential (9)(10)(11)(12). However, in vivo κOR activation is associated with side effects like anxiety, stress, diuresis, dysphoria/aversion, and psychomimetic effects (6)(7)(8). Also, activation of the κOR system has been implicated in relapse to drugs of abuse; this limits the use of κOR agonists in the treatment of drug addiction (13,14).…”
mentioning
confidence: 99%